

## WEST Search History

DATE: Friday, March 07, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L6	L5 not l3	2	L6
L5	(L3 or l2) and mutat\$	13	L5
L4	L3 and l2	15	L4
L3	factor vii activating and (protease or proteolytic)	27	L3
L2	factor vii adj2 activ\$ near3 (protease or proteolytic)	21	L2
L1	factor vii adj2 activ\$ near3 prote\$	33	L1

END OF SEARCH HISTORY

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 27 returned.**☐ 1. Document ID: US 20020142316 A1

L3: Entry 1 of 27

File: PGPB

Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142316

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020142316 A1

TITLE: Mutants of the factor VII-activating protease and detection methods using specific antibodies

PUBLICATION-DATE: October 3, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roemisch, Juergen	Marburg		DE	
Stoehr, Hans-Arnold	Wetter		DE	
Feussner, Annette	Marburg		DE	
Lang, Wiegand	Colbe		DE	
Weimer, Thomas	Gladenbach		DE	
Becker, Margret	Marburg		DE	
Nerlich, Claudia	Marburg		DE	
Muth-Naumann, Gudrun	Wetter		DE	

US-CL-CURRENT: 435/6

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KIMC</a>	<a href="#">Draw Desc</a>	<a href="#">Image</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

☐ 2. Document ID: US 20020119153 A1

L3: Entry 2 of 27

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119153

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119153 A1

TITLE: Antibody conjugate formulations for selectively inhibiting VEGF

PUBLICATION-DATE: August 29, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Brekken, Rolf A.	Seattle	WA	US	

US-CL-CURRENT: 424/145.1; 424/133.1, 530/388.24

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KIMC</a>	<a href="#">Draw Desc</a>	<a href="#">Image</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

☐ 3. Document ID: US 20020110552 A1

L3: Entry 3 of 27

File: PGPB

Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110552

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020110552 A1

TITLE: Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme

PUBLICATION-DATE: August 15, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Romisch, Jorgen	Marburg		DE	
Feussner, Annette	Marburg		DE	
Kannemeier, Christian	Marburg		DE	
Stohr, Hans-Arnold	Wetter		DE	

US-CL-CURRENT: 424/94.63

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 20020061850 A1

L3: Entry 4 of 27

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061850

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061850 A1

TITLE: Regulation of human transmembrane serine protease

PUBLICATION-DATE: May 23, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xiao, Yonghong	Cambridge	MA	US	
Gedrich, Richard W.	Guilford	CT	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6528299 B1

L3: Entry 5 of 27

File: USPT

Mar 4, 2003

US-PAT-NO: 6528299

DOCUMENT-IDENTIFIER: US 6528299 B1

TITLE: Protease for activating clotting factor VII

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

---

☐ 6. Document ID: US 6524583 B1

L3: Entry 6 of 27

File: USPT

Feb 25, 2003

US-PAT-NO: 6524583

DOCUMENT-IDENTIFIER: US 6524583 B1

TITLE: Antibody methods for selectively inhibiting VEGF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

---

☐ 7. Document ID: US 6423543 B1

L3: Entry 7 of 27

File: USPT

Jul 23, 2002

US-PAT-NO: 6423543

DOCUMENT-IDENTIFIER: US 6423543 B1

TITLE: Antisense modulation of hepsin expression

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

---

☐ 8. Document ID: US 6416758 B1

L3: Entry 8 of 27

File: USPT

Jul 9, 2002

US-PAT-NO: 6416758

DOCUMENT-IDENTIFIER: US 6416758 B1

TITLE: Antibody conjugate kits for selectively inhibiting VEGF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

---

☐ 9. Document ID: US 6342221 B1

L3: Entry 9 of 27

File: USPT

Jan 29, 2002

US-PAT-NO: 6342221

DOCUMENT-IDENTIFIER: US 6342221 B1

TITLE: Antibody conjugate compositions for selectively inhibiting VEGF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

---

☐ 10. Document ID: US 6342219 B1

L3: Entry 10 of 27

File: USPT

Jan 29, 2002

US-PAT-NO: 6342219

DOCUMENT-IDENTIFIER: US 6342219 B1

TITLE: Antibody compositions for selectively inhibiting VEGF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

[Generate Collection](#)[Print](#)

Terms	Documents
factor vii activating and (protease or proteolytic)	27

**Display Format:**

-

[Change Format](#)[Previous Page](#)[Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 27 returned.**☐ 11. Document ID: US 6312694 B1

L3: Entry 11 of 27

File: USPT

Nov 6, 2001

US-PAT-NO: 6312694

DOCUMENT-IDENTIFIER: US 6312694 B1

TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 12. Document ID: US 6160097 A

L3: Entry 12 of 27

File: USPT

Dec 12, 2000

US-PAT-NO: 6160097

DOCUMENT-IDENTIFIER: US 6160097 A

TITLE: Process for reactivating purified membrane proteins by freezing them

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 13. Document ID: US 6156321 A

L3: Entry 13 of 27

File: USPT

Dec 5, 2000

US-PAT-NO: 6156321

DOCUMENT-IDENTIFIER: US 6156321 A

TITLE: Tissue factor methods and compositions for coagulation and tumor treatment

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 14. Document ID: US 6132730 A

L3: Entry 14 of 27

File: USPT

Oct 17, 2000

US-PAT-NO: 6132730

DOCUMENT-IDENTIFIER: US 6132730 A

TITLE: Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 15. Document ID: US 6132729 A

L3: Entry 15 of 27

File: USPT

Oct 17, 2000

US-PAT-NO: 6132729

DOCUMENT-IDENTIFIER: US 6132729 A

TITLE: Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 16. Document ID: US 6031081 A

L3: Entry 16 of 27

File: USPT

Feb 29, 2000

US-PAT-NO: 6031081

DOCUMENT-IDENTIFIER: US 6031081 A

TITLE: Process for reactivating purified membrane proteins by freezing them

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 17. Document ID: US 5580744 A

L3: Entry 17 of 27

File: USPT

Dec 3, 1996

US-PAT-NO: 5580744

DOCUMENT-IDENTIFIER: US 5580744 A

TITLE: Test article and method for performing blood coagulation assays

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 18. Document ID: JP 2002249441 A

L3: Entry 18 of 27

File: JPAB

Sep 6, 2002

PUB-NO: JP02002249441A

DOCUMENT-IDENTIFIER: JP 2002249441 A

TITLE: BLOOD COAGULATION FACTOR VII-ACTIVATING-PROTEASE AND STABLE LIQUID PREPARATION CONTAINING PROENZYME THEREOF

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 19. Document ID: JP 2001029098 A

L3: Entry 19 of 27

File: JPAB

Feb 6, 2001

PUB-NO: JP02001029098A

DOCUMENT-IDENTIFIER: JP 2001029098 A

TITLE: ACTIVITY MEASUREMENT OF FACTOR VII-ACTIVATING PROTEASE CONTAINED IN PROTEIN SOLUTION

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMVC	Draw Desc	Image
------	-----------	-------

---

☐ 20. Document ID: EP 1182258 A1

L3: Entry 20 of 27

File: EPAB

Feb 27, 2002

PUB-NO: EP001182258A1

DOCUMENT-IDENTIFIER: EP 1182258 A1

TITLE: Mutants of the factor VII activating protease and methods for their detection

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMVC	Draw Desc	Image
------	-----------	-------

---

Generate Collection

Print

Terms	Documents
factor vii activating and (protease or proteolytic)	27

**Display Format:**

-

Change Format

[Previous Page](#)

[Next Page](#)



biological functions, and removal of a tag is not necessarily required prior to use of the TF construct in the present invention.

Detailed Description Text (309):

Two RIBS epitopes have been localized by Ugarova et al. (1993). One sequence resides at .gamma.112-119 and is recognized by MAb 9F9; the second is the RGDF sequence at A.alpha. 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the A.alpha.-chains to form fragment X.sub.2. The inaccessibility of the RGDF sequence at A.alpha. 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPIIb-IIIa.

Detailed Description Text (330):

Depending on the specific toxin compound used as part of the fusion protein, it may be necessary to provide a peptide spacer operatively attaching the targeting agent and the toxin compound which is capable of folding into a disulfide-bonded loop structure. Proteolytic cleavage within the loop would then yield a heterodimeric polypeptide wherein the targeting agent and the toxin compound are linked by only a single disulfide bond. See, for example, Lord et al. (1992). An example of such a toxin is a Ricin A-chain toxin.

Detailed Description Text (331):

When certain other toxin compounds are utilized, a non-cleavable peptide spacer may be provided to operatively attach the targeting agent and the toxin compound of the fusion protein. Toxins which may be used in conjunction with non-cleavable peptide spacers are those which may, themselves, be converted by proteolytic cleavage, into a cytotoxic disulfide-bonded form (see for example, Ogata et al., 1990). An example of such a toxin compound is a Pseudomonas exotoxin compound.

Detailed Description Text (344):

Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

Detailed Description Text (362):

Exemplary tTF prodrugs have the following structures: tTF.sub.1-219 (X).sub.n1 (Y) n.sub.2 Z Ligand, where tTF.sub.1-219 represents TF minus the cytosolic and transmembrane domains; X represents a hydrophobic transmembrane domain n1 amino acids (AA) in length (n=1-20 AA); Y represents a hydrophilic protease recognition sequence of n2 AA in length (sufficient AA to ensure appropriate protease recognition); Z represents a disulfide thioester or other linking group such as (Cys).sub.1-2 ; Ligand represents an antibody or other targeting moiety recognizing tumor-cells, tumor EC, connective tissue (stroma) or basal lamina markers

Detailed Description Text (363):

The tTF prodrug is contemplated for injection intravenously allowing it to localize to diseased tissue (e.g., tumor). Once localized in the diseased tissue, endogenous proteases (e.g., m et alloproteinases, thrombin, Factor Xa, Factor VIIa, Factor IXa, plasmin) will cleave the hydrophilic protease recognition sequence from the prodrug which will allow the hydrophobic transmembrane sequence to insert into a local cell membrane. Once the tail has inserted into the membrane, the tTF will regain its coagulation-inducing properties resulting in clot formation in the vasculature of the diseased tissue.

Detailed Description Text (425):

Fab fragments can be obtained by proteolysis of the whole immunoglobulin by the non-specific thiol protease, papain. Papain must first be activated by reducing the sulphhydryl group in the active site with cysteine, 2-mercaptoethanol or dithiothreitol. Heavy m et als in the stock enzyme should be removed by chelation with EDTA (2 mM) to ensure maximum enzyme activity. Enzyme and substrate are normally mixed together in the ratio of 1:100 by weight. After incubation, the reaction can be stopped by irreversible alkylation of the thiol group with iodoacetamide or simply by

dialysis. The completeness of the digestion should be monitored by SDS-PAGE and the various fractions separated by protein A-Sepharose or ion exchange chromatography.

Detailed Description Text (428):

Digestion of rat IgG by pepsin requires conditions including dialysis in 0.1 M acetate buffer, pH 4.5, and then incubation for four hours with 1% w/w pepsin; IgG.sub.1 and IgG.sub.2a digestion is improved if first dialyzed against 0.1 M formate buffer, pH 2.8, at 4.degree. C., for 16 hours followed by acetate buffer. IgG.sub.2 b gives more consistent results with incubation in staphylococcal V8 protease (3% w/w) in 0.1 M sodium phosphate buffer, pH 7.8, for four hours at 37.degree. C.

Other Reference Publication (12):

Morrissey et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for initiation of the coagulation protease cascade," Cell 50:129-135, 1987.

Other Reference Publication (24):

Ruf et al., "Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII," J. Biol. Chem. 267(31):22206-22210, 1992.

Other Reference Publication (25):

Ruf et al., "Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex," J. Biol. Chem. 267(9):6375-6381, 1992.

**WEST**

Generate Collection

Print

L3: Entry 14 of 27

File: USPT

Oct 17, 2000

DOCUMENT-IDENTIFIER: US 6132730 A

TITLE: Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Brief Summary Text (12):

In further studies connected with Tissue Factor (TF), Edgington and colleagues have shown that, in contrast to normal melanocytes, malignant metastasizing human melanoma cells express high levels of TF, the major cellular initiator of the plasma coagulation protease cascades (WO 94/28017; WO 94/05328; U.S. Pat. No. 5,437,864). It was reported that inhibition of TF function and subsequent reduction in local protease generation resulted in significantly reduced numbers of tumor cells retained in the vasculature. This led to the suggestion that there was a direct correlation between TF expression and the metastatic phenotype of tumor cells. Edgington and colleagues proposed that a function of TF is required for successful implantation of tumor cells and that interference with TF function, or specific interference with cell surface expression of TF, is useful in inhibiting metastasis. These authors have therefore proposed treating cancer with antibodies directed against Tissue Factor.

Detailed Description Text (11):

263 amino acid membrane glycoprotein (SEQ ID NO:12), and its primary sequence has structural similarity with the chemokine receptor family (Edgington et al., 1991). TF is a transmembrane cell surface receptor and functions as the receptor and cofactor for Factor VIIa. TF binds Factor VIIa to form a proteolytically active complex on the cell surface (Ruf and Edgington, 1991b, 1994; Ruf et al., 1991, 1992a, 1992b). This complex rapidly activates the serine protease zymogens Factors IX and X by limited proteolysis, leading to the formation of thrombin and, ultimately, a blood clot (FIG. 21).

Detailed Description Text (62):

this region may also prove to be relevant to the Factor VII activating activity, and one may therefore consider introducing mutations into any one or more of the residues generally located between about amino acid 106 and about amino acid 209 of the TF sequence (WO 94/07515). In terms of the preferred region, one may generally consider mutating any one or more of amino acids 147, 152, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 and/or 167. With reference to the generally preferred candidate mutations outside this region, one may refer to the following amino acid substitutions: S16, T17, S39, T30, S32, D34, V67, L104, B105, T106, R131, R136, V145, V146, F147, V198, N199, R200 and K201, with amino acids A34, E34 and R34 also being considered (WO 94/28017).

Detailed Description Text (143):

As disclosed herein in detail, the generally preferred techniques for purifying expressed TF constructs for use in the present invention involve the generation of a TF molecule that includes an affinity purification tag and the use of an affinity separation matrix for obtaining the TF construct free from most or all contaminating species. Many such fusion protein tags are known to those of ordinary skill in the art and such expression and separating protocols can be easily executed. Technology is also available for cleaving the original affinity tag prior to use of the released protein or polypeptide, which may be effected by inserting a protease-sensitive linker between the affinity tag and the protein of interest. Such methodology is indeed employed in connection with aspects of the present invention. U.S. Pat. No. 5,298,599 is also instructive in this regard. However, it is also known that many such tags do not impair the ability of the expressed protein to carry out their

biological functions, and removal of a tag is not necessarily required prior to use of the TF construct in the present invention.

Detailed Description Text (309):

Two RIBS epitopes have been localized by Ugarova et al. (1993). One sequence resides at .gamma.112-119 and is recognized by MAb 9F9; the second is the RGDF sequence at A.alpha. 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the A.alpha.-chains to form fragment X.sub.2. The inaccessibility of the RGDF sequence at A.alpha. 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPIIb-IIIa.

Detailed Description Text (330):

Depending on the specific toxin compound used as part of the fusion protein, it may be necessary to provide a peptide spacer operatively attaching the targeting agent and the toxin compound which is capable of folding into a disulfide-bonded loop structure. Proteolytic cleavage within the loop would then yield a heterodimeric polypeptide wherein the targeting agent and the toxin compound are linked by only a single disulfide bond. See, for example, Lord et al. (1992). An example of such a toxin is a Ricin A-chain toxin.

Detailed Description Text (331):

When certain other toxin compounds are utilized, a non-cleavable peptide spacer may be provided to operatively attach the targeting agent and the toxin compound of the fusion protein. Toxins which may be used in conjunction with non-cleavable peptide spacers are those which may, themselves, be converted by proteolytic cleavage, into a cytotoxic disulfide-bonded form (see for example, Ogata et al., 1990). An example of such a toxin compound is a Pseudomonas exotoxin compound.

Detailed Description Text (344):

Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

Detailed Description Text (362):

Exemplary tTF prodrugs have the following structures: tTF.sub.1-219 (X).sub.n1 (Y) n.sub.2 Z Ligand, where tTF.sub.1-219 represents TF minus the cytosolic and transmembrane domains; X represents a hydrophobic transmembrane domain n1 amino acids (AA) in length (n=1-20 AA); Y represents a hydrophilic protease recognition sequence of n2 AA in length (sufficient AA to ensure appropriate protease recognition); Z represents a disulfide thioester or other linking group such as (Cys).sub.1-2; Ligand represents an antibody or other targeting moiety recognizing tumor-cells, tumor EC, connective tissue (stroma) or basal lamina markers

Detailed Description Text (363):

The tTF prodrug is contemplated for injection intravenously allowing it to localize to diseased tissue (e.g., tumor). Once localized in the diseased tissue, endogenous proteases (e.g., m et alloproteinases, thrombin, Factor Xa, Factor VIIa, Factor IXa, plasmin) will cleave the hydrophilic protease recognition sequence from the prodrug which will allow the hydrophobic transmembrane sequence to insert into a local cell membrane. Once the tail has inserted into the membrane, the tTF will regain its coagulation-inducing properties resulting in clot formation in the vasculature of the diseased tissue.

Detailed Description Text (425):

Fab fragments can be obtained by proteolysis of the whole immunoglobulin by the non-specific thiol protease, papain. Papain must first be activated by reducing the sulphydryl group in the active site with cysteine, 2-mercaptoethanol or dithiothreitol. Heavy m et als in the stock enzyme should be removed by chelation with EDTA (2 mM) to ensure maximum enzyme activity. Enzyme and substrate are normally mixed together in the ratio of 1:100 by weight. After incubation, the reaction can be stopped by irreversible alkylation of the thiol group with iodoacetamide or simply by

dialysis. The completeness of the digestion should be monitored by SDS-PAGE and the various fractions separated by protein A-Sepharose or ion exchange chromatography.

Detailed Description Text (428):

Digestion of rat IgG by pepsin requires conditions including dialysis in 0.1 M acetate buffer, pH 4.5, and then incubation for four hours with 1% w/w pepsin; IgG.sub.1 and IgG.sub.2a digestion is improved if first dialyzed against 0.1 M formate buffer, pH 2.8, at 4.degree. C., for 16 hours followed by acetate buffer. IgG.sub.2 b gives more consistent results with incubation in staphylococcal V8 protease (3% w/w) in 0.1 M sodium phosphate buffer, pH 7.8, for four hours at 37.degree. C.

Other Reference Publication (12):

Morrissey et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for initiation of the coagulation protease cascade," Cell 50:129-135, 1987.

Other Reference Publication (24):

Ruf et al., "Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII," J. Biol. Chem. 267(31):22206-22210, 1992.

Other Reference Publication (25):

Ruf et al., "Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex," J. Biol. Chem. 267(9):6375-6381, 1992.

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: US 6320029 B1

L6: Entry 1 of 2

File: USPT

Nov 20, 2001

US-PAT-NO: 6320029

DOCUMENT-IDENTIFIER: US 6320029 B1

TITLE: Methods of production and use of liquid formulations of plasma proteins

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMC	Draw Desc	Image
-----	-----------	-------

☐ 2. Document ID: US 5925738 A

L6: Entry 2 of 2

File: USPT

Jul 20, 1999

US-PAT-NO: 5925738

DOCUMENT-IDENTIFIER: US 5925738 A

TITLE: Methods of production and use of liquid formulations of plasma proteins

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMC	Draw Desc	Image
-----	-----------	-------

[Generate Collection](#)[Print](#)**Terms****Documents**

L5 not 13

2

**Display Format:**

-

[Change Format](#)[Previous Page](#)[Next Page](#)

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 19:43:17 ON 07 MAR 2003

=> fil .eliz

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:43:26 ON 07 MAR 2003

FILE 'SCISEARCH' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 19:43:26 ON 07 MAR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 19:43:26 ON 07 MAR 2003  
 Compiled and distributed by the NTIS, U.S. Department of Commerce.  
 It contains copyrighted material.  
 All rights reserved. (2003)

FILE 'ESBIOBASE' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:43:26 ON 07 MAR 2003  
 COPYRIGHT (C) 2003 THOMSON DERWENT

=> s factor vii activating and (protease or proteolytic)  
 4 FILES SEARCHED...

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 43 Feb 13 CANCERLIT is no longer being updated  
NEWS 44 Feb 24 METADEX enhancements  
NEWS 45 Feb 24 PCTGEN now available on STN  
NEWS 46 Feb 24 TEMA now available on STN  
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 48 Feb 26 PCTFULL now contains images  
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multiframe SDI results



=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 24 DUP REM L1 (35 DUPLICATES REMOVED)

=> d 1-10

L2 ANSWER 1 OF 24 MEDLINE  
AN 2003068564 MEDLINE  
DN 22466630 PubMed ID: 12578860  
TI **Factor VII-activating protease:**  
coagulation, fibrinolysis, and atherothrombosis?.  
CM Comment on: Circulation. 2003 Feb 11;107(5):667-70  
AU Mann Kenneth G  
NC HL-46703 (NHLBI)  
SO CIRCULATION, (2003 Feb 11) 107 (5) 654-5.  
Journal code: 0147763. ISSN: 1524-4539.  
CY United States  
DT Commentary  
Editorial  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200302  
ED Entered STN: 20030212  
Last Updated on STN: 20030227  
Entered Medline: 20030226

L2 ANSWER 2 OF 24 MEDLINE DUPLICATE 1  
AN 2003068568 MEDLINE  
DN 22466634 PubMed ID: 12578864  
TI Marburg I polymorphism of **factor VII--**  
**activating protease:** a prominent risk predictor of  
carotid stenosis.  
CM Comment in: Circulation. 2003 Feb 11;107(5):654-5  
AU Willeit Johann; Kiechl Stefan; Weimer Thomas; Mair Artur; Santer Peter;  
Wiedermann Christian J; Roemisch Juergen  
CS Department of Neurology, University Clinics, Innsbruck, Austria..  
johann.willeit@uibk.ac.at  
SO CIRCULATION, (2003 Feb 11) 107 (5) 667-70.  
Journal code: 0147763. ISSN: 1524-4539.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200302  
ED Entered STN: 20030212  
Last Updated on STN: 20030227  
Entered Medline: 20030226

L2 ANSWER 3 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
AN 2003081620 EMBASE  
TI **Factor VII-activating protease:**  
Coagulation, fibrinolysis, and atherothrombosis?.  
AU Mann K.G.  
CS Dr. K.G. Mann, University of Vermont, Department of Biochemistry, C-401  
Given Building, 89 Beaumont Avenue, Burlington, VT 05405-0068, United  
States. kenneth.mann@uvm.edu  
SO Circulation, (11 Feb 2003) 107/5 (654-655).  
Refs: 18  
ISSN: 0009-7322 CODEN: CIRCAZ  
CY United States  
DT Journal; Editorial  
FS 018 Cardiovascular Diseases and Cardiovascular Surgery  
025 Hematology  
LA English

L2 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 2  
AN 2002:517916 HCAPLUS

DN 137:83616  
TI Stabilized liquid drug delivery system containing blood-coagulation  
factor VII-activating protease or  
its proenzyme  
IN Roemisch, Juergen; Stoehr, Hans-Arnold  
PA Aventis Behring GmbH, Germany  
SO Ger. Offen., 4 pp.  
CODEN: GWXXBX

DT Patent  
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10131404	A1	20020711	DE 2001-10131404	20010625
	EP 1226829	A2	20020731	EP 2001-129605	20011212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002110552	A1	20020815	US 2002-33777	20020103
	AU 2002010069	A5	20020711	AU 2002-10069	20020107
	JP 2002249441	A2	20020906	JP 2002-316	20020107
PRAI	DE 2001-10100483	IA	20010108		
	DE 2001-10131404	A	20010625		

L2 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:157176 HCAPLUS

DN 136:197598

TI Alleles of the human factor VII activating  
protease gene and their detection

IN Roemisch, Juergen; Stoehr, Hans-arnold; Feussner, Annette; Lang, Wiegand;  
Weimer, Thomas; Becker, Margret; Nerlich, Claudia; Muth-Naumann, Gudrun

PA Aventis Behring GmbH, Germany

SO Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1182258	A1	20020227	EP 2001-115691	20010705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10036641	A1	20020214	DE 2000-10036641	20000726
	DE 10052319	A1	20020411	DE 2000-10052319	20001021
	DE 10118706	A1	20021017	DE 2001-10118706	20010412
PRAI	DE 2000-10036641	A	20000726		
	DE 2000-10050040	A	20001010		
	DE 2000-10052319	A	20001021		
	DE 2001-10118706	A	20010412		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:122504 HCAPLUS

DN 136:147482

TI Preparation and usage of monoclonal antibodies to blood-coagulation  
factor VII-activating protease  
(FSAP)

IN Roemisch, Juergen; Feussner, Annette; Stoehr, Hans-Arnold; Lang, Wiegand

PA Aventis Behring G.m.b.H., Germany

SO Ger. Offen., 4 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10036641	A1	20020214	DE 2000-10036641	20000726
	EP 1182258	A1	20020227	EP 2001-115691	20010705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI  
 JP 2002291486 A2 20021008 JP 2001-224423 20010725  
 US 2002142316 A1 20021003 US 2001-912559 20010726  
 PRAI DE 2000-10036641 A 20000726  
 DE 2000-10050040 A 20001010  
 DE 2000-10052319 A 20001021  
 DE 2001-10118706 A 20010412  
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 24 MEDLINE DUPLICATE 3  
 AN 2002676486 IN-PROCESS  
 DN 22324062 PubMed ID: 12437095  
 TI **Factor VII activating protease**  
 (FSAP): a novel **protease** in hemostasis.  
 AU Romisch Jurggen  
 CS Aventis Behring GmbH, Research, Marburg, Germany.  
 SO BIOLOGICAL CHEMISTRY, (2002 Jul-Aug) 383 (7-8) 1119-24.  
 Journal code: 9700112. ISSN: 1431-6730.  
 CY Germany: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS IN-PROCESS; NONINDEXED; Priority Journals  
 ED Entered STN: 20021120  
 Last Updated on STN: 20021212

L2 ANSWER 8 OF 24 MEDLINE DUPLICATE 4  
 AN 2002389182 MEDLINE  
 DN 22133046 PubMed ID: 12138371  
 TI The frequent Marburg I polymorphism impairs the pro-urokinase activating  
 potency of the **factor VII activating**  
**protease** (FSAP).  
 AU Roemisch J; Feussner A; Nerlich C; Stoehr H-A; Weimer T  
 CS Aventis Behring GmbH, Preclinical Research & Development, Marburg,  
 Germany.. Juergen.Roemisch@aventis.com  
 SO BLOOD COAGULATION AND FIBRINOLYSIS, (2002 Jul) 13 (5) 433-41.  
 Journal code: 9102551. ISSN: 0957-5235.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200301  
 ED Entered STN: 20020725  
 Last Updated on STN: 20030202  
 Entered Medline: 20030131

L2 ANSWER 9 OF 24 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI  
 AN 2001-07582 BIOTECHDS  
 TI Purification of **factor-VII activating**  
**protease**, useful for treating blood clotting disorders, comprises  
 performing anion- and/or cation-exchange chromatography at a pH below the  
 isoelectric point;  
 downstream processing  
 AU Roemisch J; Feussner A; Stoehr H A  
 PA Aventis-Behring  
 LO Marburg, Germany.  
 PI EP 1074616 7 Feb 2001  
 AI EP 2000-114370 5 Jul 2000  
 PRAI DE 1999-1037219 6 Aug 1999  
 DT Patent  
 LA German  
 OS WPI: 2001-184356 [19]

L2 ANSWER 10 OF 24 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI  
 AN 2001-07581 BIOTECHDS  
 TI Purifying **Factor-VII-activating**  
**protease** or its precursor, useful for promoting coagulation,  
 comprises performing fractional precipitation or affinity chromatography;  
 recombinant protein purification and transgenic animal for downstream

processing and coagulation deficiency, thrombosis disease therapy and  
vulnerary activity

AU Roemisch J; Feussner A; Stoehr H A  
PA Aventis  
LO Marburg, Germany.  
PI EP 1074615 7 Feb 2001  
AI EP 2000-114348 5 Jul 2000  
PRAI DE 1999-1037218 6 Aug 1999  
DT Patent  
LA German  
OS WPI: 2001-184355 [19]

=> d 11-20

L2 ANSWER 11 OF 24 MEDLINE DUPLICATE 7  
AN 2001376590 MEDLINE  
DN 21325956 PubMed ID: 11432747  
TI Factor VII and single-chain plasminogen activator-activating  
**protease**: activation and autoactivation of the proenzyme.  
AU Kannemeier C; Feussner A; Stohr H A; Weisse J; Preissner K T; Romisch J  
CS Aventis Behring GmbH, Research, Marburg, Germany.  
SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (2001 Jul) 268 (13) 3789-96.  
Journal code: 0107600. ISSN: 0014-2956.  
CY Germany: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200109  
ED Entered STN: 20010917  
Last Updated on STN: 20010917  
Entered Medline: 20010913

L2 ANSWER 12 OF 24 MEDLINE  
AN 2001458807 MEDLINE  
DN 21395892 PubMed ID: 11505081  
TI Quantitation of the factor VII- and single-chain plasminogen  
activator-activating **protease** in plasmas of healthy subjects.  
AU Romisch J; Feussner A; Stohr H A  
CS Aventis Behring GmbH, Research, Marburg, Germany..  
Juergen.Roemisch@aventis.com  
SO BLOOD COAGULATION AND FIBRINOLYSIS, (2001 Jul) 12 (5) 375-83.  
Journal code: 9102551. ISSN: 0957-5235.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200207  
ED Entered STN: 20010816  
Last Updated on STN: 20020703  
Entered Medline: 20020702

L2 ANSWER 13 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2001:207026 BIOSIS  
DN PREV200100207026  
TI The prourokinase activating potency of the FVII- and single chain  
plasminogen activator-activating **protease** (FSAP) is  
significantly reduced in up to 10% of healthy subjects.  
AU Roemisch, J. (1); Feussner, A. (1); Stoehr, H. A. (1)  
CS (1) Research, Aventis Behring GmbH, Marburg Germany  
SO Annals of Hematology, (2001) Vol. 80, No. Supplement 1, pp. A57. print.  
Meeting Info.: 45th Annual Meeting of the Society for  
Thrombosis/Hemostasis Research Duesseldorf, Germany February 14-17, 2001  
ISSN: 0939-5555.  
DT Conference  
LA English  
SL English

L2 ANSWER 14 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2001:196164 BIOSIS  
 DN PREV200100196164  
 TI Activators of the FVII- and single chain urokinase plasminogen  
 activator-activating **protease** (FSAP.  
 AU Kannemeier, C. (1); Feussner, A. (1); Stoehr, H. A. (1); Preissner, K. T.;  
 Roemisch, J. (1)  
 CS (1) Research, Aventis Behring GmbH, Marburg Germany  
 SO Annals of Hematology, (2001) Vol. 80, No. Supplement 1, pp. A32. print.  
 Meeting Info.: 45th Annual Meeting of the Society for  
 Thrombosis/Hemostasis Research Duesseldorf, Germany February 14-17, 2001  
 ISSN: 0939-5555.  
 DT Conference  
 LA English  
 SL English

L2 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 8

AN 2000:876807 HCAPLUS  
 DN 134:26944  
 TI Method for the determination of blood coagulation factor VII activator in  
 protein solutions using antibodies and applications for blood analysis of  
 heart patients and pregnant woman  
 IN Romisch, Jurgen; Feussner, Annette; Stohr, Hans-Arnold  
 PA Aventis Behring G.m.b.H., Germany  
 SO Eur. Pat. Appl., 9 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1059359	A2	20001213	EP 2000-111738	20000602
	EP 1059359	A3	20020814		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10023923	A1	20001214	DE 2000-10023923	20000517
	CA 2311479	AA	20001210	CA 2000-2311479	20000612
	JP 2001029098	A2	20010206	JP 2000-174893	20000612
PRAI	DE 1999-19926531	A	19990610		
	DE 2000-10023923	A	20000517		

L2 ANSWER 16 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2001:95286 BIOSIS  
 DN PREV200100095286  
 TI Purification of the proenzyme form of the FVII-activator/sc-PA-activating  
**protease** and its quantification in plasmas of healthy subjects.  
 AU Roemisch, J. (1); Kannemeier, C. (1); Feussner, A. (1); Stoehr, H. A. (1);  
 Preissner, K. T.  
 CS (1) Research, Aventis Behring GmbH, Marburg Germany  
 SO Journal of Submicroscopic Cytology and Pathology, (July, 2000) Vol. 32,  
 No. 3, pp. 388. print.  
 Meeting Info.: XIth International Vascular Biology Meeting Geneva,  
 Switzerland September 05-09, 2000  
 ISSN: 1122-9497.  
 DT Conference  
 LA English  
 SL English

L2 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:690869 HCAPLUS  
 DN 131:309276  
 TI **Protease** for activating clotting factor VII and its  
 therapeutical applications  
 IN Romisch, Jurgen; Stohr, Hans-Arnold; Feussner, Annette  
 PA Centeon Pharma G.m.b.H., Germany  
 SO Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 952215	A2	19991027	EP 1999-106913	19990408
	EP 952215	A3	20020626		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 19903693	A1	19991028	DE 1999-19903693	19990320
	US 6528299	B1	20030304	US 1999-295316	19990421
	AU 9923935	A1	19991104	AU 1999-23935	19990423
	AU 748221	B2	20020530		
	JP 2000023696	A2	20000125	JP 1999-116411	19990423
PRAI	DE 1998-19818495	A	19980424		
	DE 1998-19827734	A	19980622		
	DE 1998-19851332	A	19981106		
	DE 1998-19851335	A	19981106		
	DE 1998-19851336	A	19981106		
	DE 1999-19903693	A	19990320		

L2 ANSWER 18 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 2000:256363 SCISEARCH  
GA The Genuine Article (R) Number: 290FP  
TI A new **factor VII activating protease**  
isolated from human plasma  
AU Romisch J (Reprint); Feussner A; Vermohlen S; Stohr H A  
CS CENTEON PHARMA GMBH, RES, MARBURG, GERMANY  
CYA GERMANY  
SO THROMBOSIS AND HAEMOSTASIS, (AUG 1999) Supp. [S], pp. 1320-1320.  
Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 43, LENZHALDE 3,  
D-70040 STUTTGART, GERMANY.  
ISSN: 0340-6245.  
DT Conference; Journal  
FS LIFE  
LA English  
REC Reference Count: 0

L2 ANSWER 19 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:274991 BIOSIS  
DN PREV2000000274991  
TI The FVII activating **protease** cleaves single-chain plasminogen  
activators.  
AU Roemisch, Juergen (1); Vermohlen, Sylvia; Feussner, Annette; Stoehr,  
Hans-Arnold  
CS (1) Aventis Behring GmbH, Research, D-35002, Marburg Germany  
SO Haemostasis, (March, 1999(2000)) Vol. 29, No. 5, pp. 292-299. print..  
ISSN: 0301-0147.  
DT Article  
LA English  
SL English

L2 ANSWER 20 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1999:211822 BIOSIS  
DN PREV199900211822  
TI The FVII activating **protease** mediates fibrinolytic effects  
activating single-chain plasminogen activators.  
AU Roemisch, J. (1); Feussner, A. (1); Stoehr, H.-A. (1)  
CS (1) Research, Centeon Pharma GmbH, Marburg Germany  
SO Annals of Hematology, (1999) Vol. 78, No. SUPPL. 1, pp. A24.  
Meeting Info.: 43rd Annual Meeting of the Society for Thrombosis and  
Hemostasis Mannheim, Germany February 24-27, 1999 Society for Thrombosis  
and Hemostasis  
. ISSN: 0939-5555.  
DT Conference  
LA English

=> d 21-24

L2 ANSWER 21 OF 24 MEDLINE DUPLICATE 9  
AN 1998228168 MEDLINE

DN 98228168 PubMed ID: 95692  
 TI Expression of the **factor VII activating protease**, hepsin, in situ in renal cell carcinoma.  
 AU Zacharski L R; Ornstein D L; Memoli V A; Rousseau S M; Kisiel W  
 NC HL35246 (NHLBI)  
 SO THROMBOSIS AND HAEMOSTASIS, (1998 Apr) 79 (4) 876-7.  
 Journal code: 7608063. ISSN: 0340-6245.  
 CY GERMANY: Germany, Federal Republic of  
 DT Letter  
 LA English  
 FS Priority Journals  
 EM 199807  
 ED Entered STN: 19980723  
 Last Updated on STN: 20000303  
 Entered Medline: 19980713

L2 ANSWER 22 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 10  
 AN 1998:295582 SCISEARCH  
 GA The Genuine Article (R) Number: ZG420  
 TI Expression of the **factor VII activating protease**, hepsin, in situ in renal cell carcinoma  
 AU Zacharski L R (Reprint); Ornstein D L; Memoli V A; Rousseau S M; Kisiel W  
 CS VA MED & REG OFF CTR, WHITE RIVER JCT, VT 05009 (Reprint); DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MED, HANOVER, NH 03756; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT PATHOL, HANOVER, NH 03756; UNIV NEW MEXICO, SCH MED, DEPT PATHOL, ALBUQUERQUE, NM 87131  
 CYA USA  
 SO THROMBOSIS AND HAEMOSTASIS, (APR 1998) Vol. 79, No. 4, pp. 876-877.  
 Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY.  
 ISSN: 0340-6245.  
 DT Letter; Journal  
 FS LIFE  
 LA English  
 REC Reference Count: 16

L2 ANSWER 23 OF 24 MEDLINE DUPLICATE 11  
 AN 95113879 MEDLINE  
 DN 95113879 PubMed ID: 7814421  
 TI Hepsin, a putative membrane-associated serine **protease**, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation.  
 AU Kazama Y; Hamamoto T; Foster D C; Kisiel W  
 CS Department of Pathology, University of New Mexico School of Medicine, Albuquerque 87131.  
 NC HL35246 (NHLBI)  
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Jan 6) 270 (1) 66-72.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199502  
 ED Entered STN: 19950217  
 Last Updated on STN: 20000303  
 Entered Medline: 19950203

L2 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2003 ACS  
 AN 1994:450101 HCAPLUS  
 DN 121:50101  
 TI Blood-coagulation factor III analogs unable to activate factor VII  
 IN Ruf, Wolfram; Edgington, Thomas S.  
 PA Scripps Research Institute, USA  
 SO PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DAT	APPLICATION NO.	DATE
PI	WO 9407515	A1	19940414	WO 1993-US9570	19931006
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1992-957985		19921006		

=> dis his

(FILE 'HOME' ENTERED AT 19:43:17 ON 07 MAR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 19:43:26 ON 07 MAR 2003

L1 59 S FACTOR VII ACTIVATING AND (PROTEASE OR PROTEOLYTIC)

L2 24 DUP REM L1 (35 DUPLICATES REMOVED)

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
59.20	59.41

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 19:58:11 ON 07 MAR 2003